Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Payal Goala
Observed names:
Goala, Payal,
P Goala
Institutions:
Roswell Park Comprehensive Cancer Center,
University of South Florida,
Moffitt Cancer Center
Observed institutions:
Roswell Park Comprehensive Cancer Center,
Manipal Academy of Higher Education,
University of South Florida,
Moffitt Cancer Center,
Zayed University
ORCID:
0000-0002-4571-8513
Observed ORCID:
0000-0002-4571-8513
OpenAlex ID:
A5082725442
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells
2015
·
Munawwar Ali Khan
, Madhumitha Kedhari Sundaram
, et al.
·
Evidence-based Complementary and Alternative Medicine
·
70
PDF
Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin
2014
·
Chhavi Sharma
, Andrea J. Vas
, et al.
·
Journal of Oncology
·
68
PDF
Growth inhibitory and adjuvant therapeutic potential of aqueous extract of Triticum aestivum on MCF-7 and HeLa cells.
2014
·
A Hussain
, T M Gheewala
, et al.
·
PubMed
·
17
IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy
2025
·
Payal Goala
, Yongliang Zhang
, et al.
·
Journal of Clinical Investigation
·
11
IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
2026
·
Sae Bom Lee
, Allan Pavy
, et al.
·
Nature Communications
·
6
PDF
Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
·
Blood Cancer Discovery
·
3
PDF
CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model
2026
·
Nolan J. Beatty
, Min Ma
, et al.
·
Scientific Reports
·
1
PDF
CAR T cell-driven induction of iNOS in tumor associated macrophages promotes CAR T cell resistance in B cell lymphoma
2025
·
Sae Bom Lee
, Yun Pyo Kang
, et al.
·
Blood
·
1
PDF
Abstract 4800: Modulation of Th1/Th17 axis through IFNγ-blockade alleviates Anti-CD19 CAR-T associated toxicities in a pre-clinical immune competent model
2025
·
Payal Goala
, Marco Davila
, et al.
·
Cancer Research
·
1
Investigating the role of KLRG1 in regulatory T-cells and implications for anti-tumor immunity in Non-small Cell Lung Cancer
2021
·
Arup K Bag
, Andrew R Schultz
, et al.
·
The Journal of Immunology
·
1
CD83 CAR T provides an alternative strategy to CD19-targeting in B cell malignancies
2026
·
Brian Christopher Betts
, Constanza Savid-Frontera
, et al.
·
Journal for ImmunoTherapy of Cancer
Supplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 4 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Data from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
2026
·
Mackenzie M. Lieberman
, Jason H. Tong
, et al.
CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy
2025
·
Brian Betts
, Constanza Savid-Frontera
, et al.
·
Blood
PDF
Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes
2024
·
Showkat Hamid
, Muhammad Junaid Tariq
, et al.
·
Blood
Show more works
View as search
Works count:
27
Citation count:
179
H-index:
5
I10-index:
4
Year
Topic
Type